UroGen Pharma Reports Inducement Grants Under Nasdaq Rule 5635(c)(4) UroGen Pharma Ltd. (Nasdaq: URGN), a leading biotechnology company focused on developing and commercializing innovative therapies for urothelial and specialty cancers, has announced the issuance of inducement restricted stock units (“RSUs”)…
NovaBay Pharmaceuticals Announces Special Stockholders Meeting NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) has officially announced the scheduling of a virtual Special Meeting on April 16, 2025. During this meeting, stockholders will vote on a proposal concerning…
ENCell’s EN001 Granted FDA Orphan Drug Designation for Charcot-Marie-Tooth Disease ENCell, a pioneering biopharmaceutical company specializing in cell and gene therapy CDMO and novel drug development, announced that its investigational drug EN001 has received Orphan Drug Designation (ODD) from the…
Ventus Therapeutics Showcases Caspase-4/5 as Key Therapeutic Targets in Nature Reviews Immunology Ventus Therapeutics, a clinical-stage biopharmaceutical company focused on advancing innovative small-molecule therapies for immunological, inflammatory, and neurological disorders, has announced a significant publication in the prestigious peer-reviewed journal…
Orbital Therapeutics Strengthens Leadership with the Appointment of Biopharma Veteran Geno Germano to Its Board of Directors Orbital Therapeutics, a pioneering biotechnology company focused on advancing RNA-based medicines to address a wide range of diseases, has announced the appointment of…
Leading Cancer Center Adopts Abridge AI for Oncology Documentation Abridge, a leader in AI-driven clinical documentation solutions, has announced an extensive rollout of its AI platform at Memorial Sloan Kettering Cancer Center (MSK). This deployment, set to take place throughout…
Estrella Immunopharma Receives Buy Rating from CB Capital Partners with a $14.00 Price Target Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company pioneering the development of CD19 and CD22-targeted ARTEMIS® T-cell therapies for cancer and…
LEO Pharma Survey: Chronic Hand Eczema Misunderstood and Undermanaged LEO Pharma Survey Highlights Widespread Misunderstanding and Inadequate Management of Chronic Hand Eczema Among Dermatology Providers A recent survey commissioned by LEO Pharma Inc., a global leader in medical dermatology, and…
GeneDx Expands Exome and Genome Testing Access, Adding Cerebral Palsy as a New Indication GeneDx (Nasdaq: WGS), a leading innovator in genomic insights, has announced an expansion of its genetic testing services to include cerebral palsy (CP) as an indication.…
Epredia Secures FDA 510(k) Clearance for E1000 Dx™ Digital Pathology Solution Epredia, a global leader in precision cancer diagnostics and a subsidiary of PHC Holdings Corporation (TSE: 6523), has announced that it has received U.S. Food and Drug Administration (FDA)…
Repligen Acquires 908 Devices’ Bioprocessing Analytics Portfolio for $70 Million Repligen Corporation (Nasdaq: RGEN), a leading life sciences company specializing in bioprocessing technology, has announced the acquisition of 908 Devices Inc.’s (Nasdaq: MASS) desktop portfolio, further strengthening its position in…
FDA Grants Orphan & Rare Pediatric Status to NEU-001 for Hirschsprung Disease Neurenati Therapeutics Inc., a biotechnology company specializing in rare pediatric diseases, has announced a significant regulatory milestone. The U.S. Food and Drug Administration (FDA) has granted both Orphan…